Snady H, Rosman A S, Korsten M A
Section of Gastroenterology, VA Medical Center, Bronx, New York.
Gastrointest Endosc. 1989 Sep-Oct;35(5):377-80. doi: 10.1016/s0016-5107(89)72838-8.
In order to evaluate the effectiveness of an intensive acid protection regimen in preventing sclerotherapy-associated esophageal strictures, 62 patients undergoing sclerotherapy were randomized to receive either acid protection (antacids, cimetidine, and sucralfate) or no acid protection. Of 31 patients (38.7%) in the no acid protection group, 12 developed a symptomatic stricture during the course of sclerotherapy compared with 3 patients (9.7%) in the group assigned to acid protection (p less than 0.01). Our study demonstrates that a vigorous acid protection regimen will help prevent symptomatic esophageal strictures associated with variceal sclerotherapy.
为了评估强化胃酸保护方案在预防硬化剂治疗相关食管狭窄方面的有效性，62例接受硬化剂治疗的患者被随机分为两组，一组接受胃酸保护（使用抗酸剂、西咪替丁和硫糖铝），另一组不接受胃酸保护。在未接受胃酸保护的31例患者（38.7%）中，有12例在硬化剂治疗过程中出现了有症状的狭窄，而在接受胃酸保护的组中，这一比例为3例（9.7%）（P<0.01）。我们的研究表明，积极的胃酸保护方案有助于预防与静脉曲张硬化剂治疗相关的有症状的食管狭窄。
